报告人：Hsin-Cheng Chiu (邱信程)教授

   报告人单位：台湾清华大学

   报告时间：11月30号下午14:00

   地点：润德楼B511

   举办单位：欧洲杯线上买球

   报告人简介

Hsin-Cheng Chiu (邱信程)，台湾清华大学生医工程与环境科学系教授，曾任台湾清华大学原子科学院副院长、台湾生医材料及药物制放学会理事长、President of the Controlled Release Society Chinese Taipei Local Chapter、台湾生医材料及药物制放学会常务理事等职务。

主要从事药物传递系统、生物医用材料等领域的研究，相关研究成果发表在Biomaterials、 Advanced Functional Materials、Angewandte Chemie International Edition等领域TOP期刊上，先后荣获台湾109年度科技部杰出研究奖、Fellow of Biomaterials Science & Engineering (FBSE) of the International Union of Societies for Biomaterials Science and Engineering (IUSBSE)、李昭仁教授纪念基金会杰出研究学者奖、李昭仁教授纪念基金会生医工程奖、台湾科技大学杰出校友等荣誉奖项。

报告内容简介

This work aims to develop functionalized solid lipid nanoparticles (SLNs) as an oral drug delivery system for improving the efficacy of colon cancer therapy. Doxorubicin (DOX)/superparamagnetic iron oxide nanoparticle (SPION)-loaded SLNs were prepared by double emulsion method and sequentially coated with folate-modified D-α-Tocopherol polyethylene glycol 1000 succinate (TPGS) and octadecanol-conjugated dextran. The dextran/folate-coated SLNs (DFSLNs) loaded with DOX and SPION had a particle size of ca. 132 nm. The loading contents of DOX and SPION were ca. 9.27 and 0.72 wt%, respectively. Compared to the uncoated SLNs, the folate-containing SLNs were significantly internalized by CT26 cancer cells with overexpressed folate receptor, thus increasing the intracellular DOX concentration by 2-fold. Similarly, the DFSLNs with dextranase pre-treatment exhibited an identical increase of DOX concentration within the cancer cells, indicating that the exposed folate ligands upon the detachment of the outer dextran layers due to enzymatic degradation appreciably promoted the cellular uptake of DFSLNs by folate-receptor mediated endocytosis. The in vivo characterization showed that the orthotopic CT26 tumor-bearing mice orally administrated with DFSLNs and treated with high frequency magnetic field exhibited the best colorectal drug accumulation and tumor growth inhibition. Moreover, the abdominal metastasis of CT26 colon tumor was also reduced by the chemo/thermal combination therapy of DFSLNs. These results demonstrate that the developed DFSLNs employed as an oral drug delivery system has great potential for colon cancer therapy.